Damage to yeast cells of Cryptococcus neoformans by voriconazole and fluconazole: A culture and microscopic study

Medical Mycology

Volumn 36, Issue 4, 1998, Pages 227-233

  Brummer, E ^a,b   Kamei, K ^a   Miyaji, M ^a  

^a CHIBA UNIVERSITY   (Japan)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

Cryptococcus neoformans; Damage; Fluconazole; Voriconazole

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ARTICLE; CELL COUNT; CELL CULTURE; CELL STRUCTURE; CELL VACUOLE; CELL VIABILITY; COLONY FORMING UNIT; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; FUNGICIDAL ACTIVITY; IN VITRO STUDY; INTERMETHOD COMPARISON; MICROSCOPY; VITAL STAIN;

ANTIFUNGAL AGENTS; COLORING AGENTS; CRYPTOCOCCUS NEOFORMANS; FLUCONAZOLE; HUMANS; PYRIMIDINES; TIME FACTORS; TRIAZOLES;

FILOBASIDIELLA NEOFORMANS;

EID: 0031928825     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-280X.1998.00155.x     Document Type: Article

References (14)

1. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Tentative Standard M27-T. Wayne, PA: NCCLS, 1995.
2. Nassar F, Brummer E, Stevens DA. Macrophage colony-stimulating factor (M-CSF) induction of enhanced anticryptococcal activity in human monocyte-derived macrophages: synergy with fluconazole for killing. Cell Immunol 1995; 164: 113-118.
3. Brummer E, Stevens DA. Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing. J Infect Dis 1994; 170: 173-179.
4. Brummer E, Nassar F, Stevens DA. Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing. Antimicrob Agents Chemother 1994; 38: 2158-2161.
5. Nassar F, Brummer E, Stevens DA. Different components in human serum inhibit multiplication of Cryptococcus neoformans and enhance fluconazole activity. Antimicrob Agents Chemother 1995; 39: 2490-2493.
6. Grover DD, Brummer E, Stevens DA. Study of the role of iron in the anticryptococcal activity of human serum and fluconazole. Mycopathologia 1996; 133: 71-77.
7. Howard DH. Comparative sensitivity of Histoplasma capsulatum conidiospores and blastospores to oxidative antifungal systems. Infect Immun 1981; 32: 381-387.
8. Sugar AM, Chahal RS. Brummer E, Stevens DA. Susceptibility of Blastomyces dermatitidis strains to products of oxidative metabolism. Infect Immun 1983; 41: 908-912.
9. Miller MF, Mitchell TG. Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun 1991; 59: 24-28.
10. McGinnis MR, Pasarell L, Sutton DA, Fothergill AW, Cooper CR, Rinaldi MG. In vitro evaluation of voriconazole against some clinically important fungi. Antimicrob Agents Chemother 1997; 41: 1832-1834.
11. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997; 41: 1840-1842.
12. Clacy CJ, Yu CY, Nguyen MH. In vitro activity of voriconazole against yeasts and comparison with fluconazole. In: Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotheraphy Meeting, Toronto, Canada. Washington, DC: American Society for Microbiology, 1997:129 (Abstract E-88).
13. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol 1997; 97: 663-665.
14. Kolotila MP, Smith CW, Rogers AL. Candidacidal activity of macrophages from three mouse strains as demonstrated by a new method: neutral red staining. J Med Vet Mycol 1987; 25: 283-290.